Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

About this update from Ai, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/df6c1139043249c9ab20f3244b03a84f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/u8XzegGe7P3IosU67zk3EQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/df6c1139043249c9ab20f3244b03a84f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/wqpDa2CY_IPp54nMqpHwLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/df6c1139043249c9ab20f3244b03a84f","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, April 14, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego.","length":345,"tagName":"p"},{"type":"text","content":""The research that Tempus is presenting at this year’s AACR annual meeting underscores the scale and real-world impact of Tempus’ multimodal dataset and AI-enabled diagnostic solutions," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "Across these studies, our researchers are uncovering clinically relevant insights that not only deepen our understanding of tumor biology, but also have the potential to transform how cancer is diagnosed and treated. This work is a product of our ongoing commitment to advancing the field of oncology and, ultimately, to improving outcomes for the patients we serve."","length":634,"tagName":"p"},{"type":"text","content":"Tempus will host an Exhibitor Spotlight Theater session on Monday, April 20, 2026, from 10:00–11:00 AM PST in Theater B of the Sails Pavilion. In "Beyond the Pilot: Scaling Multimodal AI and Lab-in-the-Loop for Breakthrough R&D," Sasser and Neil Bence, PhD, Senior Vice President of the Protein Homeostasis Thematic Research Center at Bristol Myers Squibb, will explore how combining deep molecular insights with high-throughput Lab-in-the-Loop functional screening can accelerate breakthroughs.","length":509,"tagName":"p"},{"type":"text","...

More updates from Ai, Inc.